ArticleJournal of ovarian research2019

Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer.

Katherine Redd Bowman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.